

A dark blue horizontal banner with a white circle on the left side containing the text 'PRESS RELEASE' in white, uppercase letters.

PRESS RELEASE

Sosei Heptares Webinar Presentation for FY2023 Financial Results

Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024.

The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, Head of UK R&D and Satoshi Tanaka, Executive Officer and Executive Vice President of Sosei Heptares and President of Idorsia Pharmaceuticals Japan at 5 pm JST (8 am GMT) on Tuesday, 13 February 2024.

The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&A session. Please click [here](#) to pre-register, which will provide a link to access the webinar.

Presentation slides will be made available by 4 pm JST (7 am GMT) on 13 February through the investor section of the Company’s Home Page [here](#).

– ENDS –

Enquiries:

Sosei Heptares – Media and Investor Relations

Kentaro Tahara, VP Investor Relations and Corporate Strategy
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@SoseiHeptares.com

MEDiSTRAVA Consulting (for International Media)

Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | SoseiHeptares@medistrava.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.